微肿瘤模型构建及其药敏检测技术中国专家共识(2023年版)

Chinese experts consensus on the construction of patient-derived tumor-like cell cluster (PTC) model and anti-tumor drug sensitivity detection technology (2023 Version)

摘要:

患者来源类肿瘤细胞簇 （Patient-Derived Tumor-Like Cell Cluster，PTC） 简称微肿瘤或微肿瘤 PTC，是一种新型的原代3D肿瘤模型，该模型在病理组织学特征、分子遗传学特征方面保持了跟原始肿瘤组织的高度相似性。同时，该模型在培养过程中保留了原始肿瘤组织中的成纤维细胞和免疫细胞，从而高度还原了原始肿瘤组织微环境特征。微肿瘤PTC 模型可广泛的应用于肿瘤基础科学研究、精准治疗和新药研发等领域。然而，由于微肿瘤PTC模型的构建及应用涉及到多种技术，流程多，影响因素多，目前，国内对微肿瘤PTC模型构建、鉴定、药敏检测等操作尚未建立规范标准。为此，特组织编写《微肿瘤模型构建及药敏检测技术中国专家共识 （2023年版）》，以利于推动和指导微肿瘤PTC模型构建以及基于此模型药敏检测技术的应用。

Abstract:

The patient-derived tumor-like cell cluster (PTC), also known as mini-tumor, represents a novel 3D tumor model with a high resemblance to the original tumor tissue in terms of histopathological and genetic characteristics. Notably, PTCs include stromal cells such as fibroblasts and various immune cells, effectively recapitulating the microenvironment of the original tumor tissue. With broad applications in basic scientific research, precision medicine, and drug discovery, the construction and utilization of PTCs involve intricate technical processes. However, the absence of a standardized procedure for PTC construction, identification, and drug sensitivity detection poses a challenge. Addressing this gap, we present the "Chinese expert consensus on the construction of patient-derived tumor-like cell cluster (PTC) model and anti-tumor drug sensitivity detection technology (2023 Version). " This consensus aims to enhance the comprehension of the PTC model and provide guidance for its application in anti-tumor drug sensitivity testing.